Journal article
The effects of monoclonal anti‐CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia
- Abstract:
-
BACKGROUND
CD47 is a novel therapeutic target in the treatment of solid‐organ and hematologic malignancies. CD47 is also expressed on RBCs. Here, we report our experience of the RBC effects and the impact on blood bank testing and transfusion management in a Phase 1 trial of the humanized anti‐CD47 monoclonal antibody Hu5F9‐G4 in relapsed or primary refractory acute myeloid leukemia (AML) (NCT02678338).
STUDY DESIGN AND METHODS
Ninete...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Transfusion Journal website
- Volume:
- 59
- Issue:
- 7
- Pages:
- 2248-2254
- Publication date:
- 2019-06-10
- Acceptance date:
- 2019-04-01
- DOI:
- EISSN:
-
1537-2995
- ISSN:
-
0041-1132
- Pmid:
-
31183877
- Source identifiers:
-
1012664
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:1012664
- UUID:
-
uuid:3822e025-6475-4585-9b1c-424ab04d51a0
- Local pid:
- pubs:1012664
- Deposit date:
- 2019-06-25
Terms of use
- Copyright holder:
- AABB
- Copyright date:
- 2019
- Rights statement:
- © 2019 AABB.
- Notes:
- This is the accepted manuscript version of the article. The final version is available online from Wiley at: https://doi.org/10.1111/trf.15397
If you are the owner of this record, you can report an update to it here: Report update to this record